Patients’ and Physicians’ Preferences for Treatments in mCRC
Research type
Research Study
Full title
Patients’ and Physicians’ Preferences for Treatments in Metastatic Colorectal Cancer
IRAS ID
345034
Contact name
Christine Michaels-Igbokwe
Contact email
Sponsor organisation
Takeda
Duration of Study in the UK
0 years, 6 months, 17 days
Research summary
This study aims to understand treatment preferences among patients with advanced metastatic colorectal cancer (mCRC) and the physicians who treat them. Specifically, it focuses on those receiving third-line treatments or beyond. The purpose is to learn what treatment characteristics are most important to both groups, especially with the introduction of new mCRC treatments.
Researchers plan to use surveys to ask patients and doctors about various features of treatments, like how they are administered, their side effects, and the expected outcomes in terms of survival and disease progression. The study will explore which benefits and risks patients and doctors consider acceptable when choosing a treatment. Additionally, it will examine how personal characteristics of both patients and physicians influence their preferences.
Participants in the study will include mCRC patients who have already undergone at least two other drug treatments and physicians who have significant experience treating this type of cancer. All participants must be from Canada, the US, the UK, or Germany and must be able to understand English or German.
The survey will first be tested in a smaller pilot group to ensure questions are relevant and understandable. This phase will include five patients and five physicians. The main study will then survey 150 patients and 75 physicians.
Data analysis will focus on understanding how treatment preferences vary and identifying common themes from the survey responses. Researchers will also use a method called multi-attribute utility theory to understand how different treatment characteristics are valued.
The study aims to provide insights that could help in tailoring treatment approaches to better meet the needs and preferences of patients and doctors, enhancing overall patient care in metastatic colorectal cancer. Limitations include the potential for biases that will be addressed through careful study design and preliminary testing.REC name
West Midlands - Solihull Research Ethics Committee
REC reference
24/WM/0193
Date of REC Opinion
19 Sep 2024
REC opinion
Unfavourable Opinion